retatrutide mechanism clinical trials for Obesity retatrutide mechanism clinical trials (RETA)

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S: Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

Because of the low-carb diets effect on blood sugar, it may also have some benefit for people with type 2 diabetes

Potential Benefits: Significant Weight Loss: When combined with GLP-1 therapy, Cagrilintide has led to greater reductions in body weight than GLP-1s alone in clinical trials

Early animal and human studies have reported encouraging findings, but evidence from large and diverse populations remains limited

I wanted to do something more natural, she says